Biogen’s inherited eye disease gene therapy misses the mark in late-stage trial

Biogen has announced that a late-stage trial of its gene therapy timrepigene emparvovec did not meet its primary and key secondary endpoints in patients with the rare inherited eye disease choroideremia.